Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation
Journal
Clinical and molecular hepatology
Journal Volume
30
Journal Issue
1
Pages
98
Date Issued
2024-01
Author(s)
Tsai, Ying-Nan
Wu, Jia-Ling
Tseng, Cheng-Hao
Chen, Tzu-Haw
Wu, Yi-Ling
Yang, Tzeng-Huey
Nguyen, Mindie H
Hsu, Yao-Chun
Abstract
Finite nucleos(t)ide analog (NA) therapy has been proposed as an alternative treatment strategy for chronic hepatitis B (CHB), but biomarkers for post-treatment monitoring are limited. We investigated whether measuring hepatitis B core-related antigen (HBcrAg) after NA cessation may stratify the risk of subsequent clinical relapse (CR).
Subjects
Antiviral treatment; Chronic hepatitis B; Finite nucleos(t)ide analog therapy; Hepatitis B core-related antigen
Type
journal article